THE FACTORS INFLUENCING THE DURATION OF SUBCUTANEOUS SEROMA AFTER BREAST CANCER SURGERY
Keywords:
breast cancer, surgical treatment, subcutaneous seroma, risk factors.Abstract
Summary. The most frequent complication of surgical treatment of patients with breast cancer (BC) is formation of subcutaneous seroma (SS). Pathogenesis of the last is not certain, the generally accepted algorithms of prophylaxis and
treatment are not worked out. Aim: to conduct the retrospective analysis of clinical risk factors that influence on duration
of existence SS for development and introduction of protocols
of its prophylaxis and treatment. Object and methods: in research it is included 80 patients with BC stage I–III (Т1–
4N0–3M0); 50 from them were performed a radical mastectomy, 30— organospearing operation. SS was counted by
the accumulations (by volume of >10 ml) of exudate and/or
lymph in the area of postoperative wound, that required repeated puncture with the aim of evacuation. Estimated connection between duration SS and by clinical descriptions:
age in the moment of raising of diagnosis, tumor size, presence of metastases in regional lymphonoduss, realizations of
neoadjuvant chemotherapy, volume of surgical interference,
duration of postoperative wound drainage, concomitant diseases (hypertensive illness, diabetes mellitus type 2, obesity
(body mass index). Results: duration SS < 7 days after an
operation set in 40 (50.0%) patients, 7–14 days — in 24
(30.0%), > 14 days — in 16 (20.0%). Duration of SS correlates with the volume of operation (r = 0.893; p < 0.05),
the body mass index (obesity) (r = 0.607; p< 0.05), the age
of patients (r = 0.526; p < 0.05), the level of glycemia on an
empty stomach (diabetes mellitus type 2) (r = 0.513; p <
0.05); a less measure— with the tumor size (r= 0.377) and
the drainage duration of postoperative wound (r = 0.342).
Conclusion: patients with BC at the age of ≥ 50 years; with
obesity, and/or hypertensive illness, and/or diabetes mellitus type 2, as RМЕ that is planned, need the active prophylaxis of forming SS.
References
Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN
v1.0, Cancer Incidence and Mortality Worldwide: IARC
CancerBase No. 11 [Internet]. Lyon, France: International Agency
for Research on Cancer; 2013. Available from: http://globocan.iarc.
fr, accessed on 02/12/2016.
Рак в Україні 2014–2015. Захворюваність, смертність,
показники діяльності онкологічної служби. Бюл Нац канцерреєстру України 2016; (17): 46–7.
Classe J, Dupre PF, François T, et al. Axillary padding
as an alternative to closed suction drain for ambulatory axillary
lymphadenectomy. A prospective cohort of 207 patients with early
breast cancer. Arch Surg 2002; 137: 169–73.
Aitken DR, Minton JP. Complications associated with
mastectomy. Surg Clin North Am 1983; 63: 1331–52.
Oertli D. Axillary lymphadenectomy. Chirurg 2000; 78:
–202.
Kuroi K, Shimozuma K, Taguchi T, et al. Pathophysiology of
seroma in breast cancer. Breast Cancer 2005; 12: 288–93.
Yiping Gong MB, Juan Xu MB, Jun Shao MS, et al.
Prevention of seroma formation after mastectomy and axillary
dissection by lymph vessel and dead space closure: a randomized
trial. Am J Surg 2010; 200: 352–6.
Akinci M, Cetin B, Aslan S, Kulacoglu H. Factors affecting
seroma formation after mastectomy with full axillary dissection.
Acta Chir Belg 2009; 109: 481–3.
Tadych K, Donegan WL. Postmastectomy seromas and
wound drainage. Surg Gynecol Obstet 1987; 165: 483–7.
Gonzalez EA, Saltzstein EC, Riedner CS, Nelson BK. Seroma
formation following breast cancer surgery. Breast J 2003; 9: 385–8.
Pogson CJ, Adwani A, Ebbs SR. Seroma following breast
cancer surgery. Eur J Surg Oncol 2003; 29: 711–7.
Лапач СН, Чубенко АВ, Бабич ПН. Статистика в науке и бизнесе. К.: МОРИОН, 2002. 640 с.
Boostrom SY. Incidence of clinically significant seroma after
breast and axillary surgery. J Am Coll Surg 2009; 208 (1): 148–50.
Stehbens WE. Postmastectomy serous drainage and seroma:
probable pathogenesis and prevention. ANZ J Surg 2003; 73: 877–80.
